| Literature DB >> 16368883 |
Derek L Stirewalt1, Kenneth J Kopecky, Soheil Meshinchi, Julia H Engel, Era L Pogosova-Agadjanyan, Jeremy Linsley, Marilyn L Slovak, Cheryl L Willman, Jerald P Radich.
Abstract
FLT3 internal tandem duplications (FLT3/ITDs) in the juxtamembrane domain are found in approximately 25% of acute myeloid leukemia (AML) patients, ranging in size from 3 to hundreds of nucleotides. We examined whether the sizes of FLT3/ITDs were associated with clinical outcomes in 151 AML patients enrolled in Southwest Oncology Group studies: S9333 and S9500. FLT3/ITDs were identified in 32% of patients (median ITD size = 39 nucleotides; range, 15-153 nucleotides). The CR rates were 35%, 67%, and 52% for patients with large (>or= 40), small (< 40), and no ITDs, respectively (P = .19). Increasing ITD size was associated with decreasing OS (estimated 5-year OS: large = 13%, small = 26%, and no ITD = 21%, P = .072) and RFS (estimated 5-year RFS: large = 13%, small = 27%, and no ITD = 34%, P = .017). These studies suggest that ITD size may have prognostic significance.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16368883 PMCID： PMC1895777 DOI： 10.1182/blood-2005-08-3453
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113